Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Perspective Therapeutics (CATX) Non-Current Deffered Revenue (2024 - 2025)

Perspective Therapeutics' Non-Current Deffered Revenue history spans 2 years, with the latest figure at $26.6 million for Q3 2025.

  • For Q3 2025, Non-Current Deffered Revenue changed 0.0% year-over-year to $26.6 million; the TTM value through Sep 2025 reached $26.6 million, changed 0.0%, while the annual FY2024 figure was $26.6 million, N/A changed from the prior year.
  • Non-Current Deffered Revenue for Q3 2025 was $26.6 million at Perspective Therapeutics, roughly flat from $26.6 million in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $26.6 million in Q1 2024 and bottomed at $26.6 million in Q1 2024.